EA017286B1 - Ингибиторы гамма-секретазы - Google Patents

Ингибиторы гамма-секретазы Download PDF

Info

Publication number
EA017286B1
EA017286B1 EA201070278A EA201070278A EA017286B1 EA 017286 B1 EA017286 B1 EA 017286B1 EA 201070278 A EA201070278 A EA 201070278A EA 201070278 A EA201070278 A EA 201070278A EA 017286 B1 EA017286 B1 EA 017286B1
Authority
EA
Eurasian Patent Office
Prior art keywords
phenyl
methyl
compound
compounds
amyloid
Prior art date
Application number
EA201070278A
Other languages
English (en)
Russian (ru)
Other versions
EA201070278A1 (ru
Inventor
Мелинда Джой Хоуп Миллер
Уоррен Джей Портер
Джон Кэвин Рил
Алмудена Рубио-Эстебан
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201070278A1 publication Critical patent/EA201070278A1/ru
Publication of EA017286B1 publication Critical patent/EA017286B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EA201070278A 2007-08-14 2008-08-04 Ингибиторы гамма-секретазы EA017286B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95572007P 2007-08-14 2007-08-14
PCT/US2008/072049 WO2009023453A1 (en) 2007-08-14 2008-08-04 Azepine derivatives as gamma-secretase inhibitors

Publications (2)

Publication Number Publication Date
EA201070278A1 EA201070278A1 (ru) 2010-06-30
EA017286B1 true EA017286B1 (ru) 2012-11-30

Family

ID=39811736

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070278A EA017286B1 (ru) 2007-08-14 2008-08-04 Ингибиторы гамма-секретазы

Country Status (11)

Country Link
US (1) US8188069B2 (OSRAM)
EP (1) EP2178844A1 (OSRAM)
JP (1) JP5385904B2 (OSRAM)
KR (1) KR101136260B1 (OSRAM)
CN (1) CN101778826B (OSRAM)
AU (1) AU2008287124B2 (OSRAM)
BR (1) BRPI0815135A2 (OSRAM)
CA (1) CA2694209C (OSRAM)
EA (1) EA017286B1 (OSRAM)
MX (1) MX2010001754A (OSRAM)
WO (1) WO2009023453A1 (OSRAM)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
CA2743436C (en) 2008-11-24 2017-10-31 Massachusetts Eye & Ear Infirmary Pathways to generate hair cells
TWI530489B (zh) 2011-03-22 2016-04-21 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯二氮呯酮化合物
US20130060023A1 (en) * 2011-09-07 2013-03-07 Satori Pharmaceuticals, Inc. Compounds useful for treating neurodegenerative disorders
JP6486272B2 (ja) 2012-09-07 2019-03-20 マサチューセッツ・アイ・アンド・イア・インファーマリー 有毛細胞および／または支持細胞再生のための方法および組成物
EP3970725B1 (en) 2012-09-07 2025-08-20 Massachusetts Eye & Ear Infirmary A gamma secretase inhibitor for treating hearing loss
US9242940B2 (en) 2012-09-21 2016-01-26 Bristol-Myers Squibb Company N-substituted bis(fluoroalkyl)-1,4-benzodiazepinone compounds
EP2897954B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
JP2015534553A (ja) 2012-09-21 2015-12-03 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 置換１，５−ベンゾジアゼピノン化合物
EP2897941B1 (en) 2012-09-21 2016-09-07 Bristol-Myers Squibb Company Prodrugs of 1,4-benzodiazepinone compounds
EP2897938B1 (en) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
TWI614238B (zh) 2012-09-21 2018-02-11 必治妥美雅史谷比公司 雙（氟烷基）－１，４－苯并二氮呯酮化合物及其前藥
CN104797584A (zh) 2012-09-21 2015-07-22 百时美施贵宝公司 作为notch抑制剂的三环杂环化合物
WO2014047397A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Fluoroalkyl and fluorocycloalkyl 1,4-benzodiazepinone compounds as notch|inhibitors
WO2014047374A1 (en) 2012-09-21 2014-03-27 Bristol-Myers Squibb Company Alkyl, fluoroalkyl-1,4-benzodiazepinone compounds
CN105101968A (zh) 2013-04-04 2015-11-25 百时美施贵宝公司 治疗增殖性疾病的组合疗法
WO2015073524A1 (en) * 2013-11-12 2015-05-21 Drexel University Novel methods of treating or preventing alzheimer's disease
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
EP3212773B1 (en) 2014-10-29 2021-09-15 Massachusetts Eye and Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
WO2017096233A1 (en) 2015-12-04 2017-06-08 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
AU2017212655B2 (en) 2016-01-29 2024-01-18 Decibel Therapeutics, Inc. Expansion and differentiation of inner ear supporting cells and methods of use thereof
RU2754452C2 (ru) 2016-04-12 2021-09-02 Эли Лилли Энд Компани Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака
ES2881801T3 (es) 2016-04-12 2021-11-30 Lilly Co Eli Terapia de combinación con inhibidores de Notch y CDK4/6 para su uso en el tratamiento de cáncer de pulmón
EP3458076A4 (en) 2016-05-16 2020-01-22 The General Hospital Corporation HUMAN RESPIRATORY STEM CELLS IN BREEDING LUNG EPITHEL
KR102463617B1 (ko) 2016-05-20 2022-11-03 일라이 릴리 앤드 캄파니 Notch 및 PD-1 또는 PD-L1 억제제를 이용한 조합 요법
EP3525796A1 (en) 2016-10-12 2019-08-21 Eli Lilly and Company Targeted treatment of mature t-cell lymphoma
JP6904612B2 (ja) 2016-12-16 2021-07-21 パイプライン セラピューティクス， インコーポレイテッド 蝸牛シナプス障害を処置する方法
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
US11590152B2 (en) 2018-01-26 2023-02-28 Massachusetts Eye And Ear Infirmary Treatment of hearing loss
TWI848951B (zh) 2018-06-01 2024-07-21 瑞士商諾華公司 針對ｂｃｍａ之結合分子及其用途
CA3144324A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2004031154A1 (en) * 2002-10-03 2004-04-15 Astrazeneca Ab Novel lactams and uses thereof
WO2004080983A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel lactams and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA74849C2 (en) 2000-11-17 2006-02-15 Lilly Co Eli Lactam
US7468365B2 (en) * 2000-11-17 2008-12-23 Eli Lilly And Company Lactam compound

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998028268A2 (en) * 1996-12-23 1998-07-02 Elan Pharmaceuticals, Inc. CYCLOALKYL, LACTAM, LACTONE AND RELATED COMPOUNDS AS β-AMYLOID PEPTIDE RELEASE INHIBITORS
WO2004031154A1 (en) * 2002-10-03 2004-04-15 Astrazeneca Ab Novel lactams and uses thereof
WO2004080983A1 (en) * 2003-03-14 2004-09-23 Astrazeneca Ab Novel lactams and uses thereof

Also Published As

Publication number Publication date
US8188069B2 (en) 2012-05-29
CN101778826B (zh) 2012-10-31
KR101136260B1 (ko) 2012-04-19
EP2178844A1 (en) 2010-04-28
AU2008287124B2 (en) 2013-06-06
US20100197660A1 (en) 2010-08-05
CN101778826A (zh) 2010-07-14
JP2010536766A (ja) 2010-12-02
KR20100032924A (ko) 2010-03-26
EA201070278A1 (ru) 2010-06-30
AU2008287124A1 (en) 2009-02-19
CA2694209A1 (en) 2009-02-19
JP5385904B2 (ja) 2014-01-08
CA2694209C (en) 2013-09-17
WO2009023453A1 (en) 2009-02-19
MX2010001754A (es) 2010-05-14
BRPI0815135A2 (pt) 2015-02-03

Similar Documents

Publication Publication Date Title
EA017286B1 (ru) Ингибиторы гамма-секретазы
EP1341531B1 (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis
US7923563B2 (en) Amorphous object of cinnamide compound
EP0942923A2 (en) N-(ARYL/HETEROARYL) AMINO ACID DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING $g(b)-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS
US6432944B1 (en) Benzodiazepinone β-amyloid inhibitors: arylacetamidoalanyl derivatives
US6495693B2 (en) N-(aryl/heteroaryl) amino acid derivatives, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds
RU2655454C2 (ru) Соли сульфаты n-(3-(4-(3-(диизобутиламино)пропил)пиперазин-1ил)пропил)-1н-бензо[d]имидазол-2-амина, их получение и их применение
EA006919B1 (ru) Соединение лактама
US6696488B2 (en) (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
JP2003513958A (ja) β−アミロイドペプチド放出および／またはその合成を阻害するために有用なβ−アミノ酸化合物
US4719222A (en) Pharmacologically active 5-oxo-1-imidazolidine acetamide compounds
US6617426B1 (en) Cysteinyl protease inhibitors
WO2001034639A2 (en) β-AMINOACID COMPOUNDS USEFUL FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS
HK1059731B (en) Lactam compound to inhibit beta-amyloid peptide release or synthesis

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU